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Dr. Seki’s study presents a relatively unusual pe-
diatric population. Of the 68 patients studied, 18
were nonresponders to prior treatment and 50
were previously untreated. This large sample of un-
treated patients provides an excellent opportunity
for study.
Dr. Seki noted that the initiation protocol for zon-
isamide administration was 2mg/kg per day, given
twice daily, morning and evening. However, he soon
observed that the drug was better tolerated when
started at 1mg/kg per day. Most patients, including
children, will tolerate this drug better if the rate of
increase is also slowed down.
Of 44 patients with symptomatic or cryptogenic
localization related epilepsy, excellent results
were observed in 36 (82%), and a good response
was reported in 4 others. Only 4 had either a poor
response or no response. For the patients with
generalized epilepsy, excellent responses were ob-
served in 10 of 11 of the symptomatic cryptogenic
and 8 of 9 of the idiopathic patients. For simple
partial, complex partial, and secondarily general-
ized epilepsy patients, up to 90% of responses were
excellent or good.
However, if we start to look at patients with
West syndrome, Lennox–Gastaut syndrome, and en-
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cephalopathic epilepsy, the results may not be as
good. The greatest need in the United States right
now is for epileptic agents to treat encephalopathic
epilepsies. If zonisamide proved to be a very potent
agent for the myoclonic epilepsies of infancy—no
matter what their etiology—we would want this to
be one of the ﬁrst indications. If it is a good agent
for the myoclonic type of Lennox–Gastaut syn-
drome, we would want to explore this indication
further.
The adverse events, particularly neurotoxicity
and hypohidrosis, are of concern. In the open-label
multicenter studies, the incidence of hypohidrosis
was only 1 in 1008 patients. However, if we look
at the number of cases reported in this study2 plus
those in other subsequent studies, the current total
is approximately 20.
We can conclude from this paper that zon-
isamide is an excellent drug for partial and gen-
eralized seizures, particularly those of idiopathic
origin. It is well tolerated if dosed correctly,
and monotherapy is successful. Clearly this is a
monotherapeutic drug and it should be used that
way whenever possible. We need to further explore
the indications and continue to deﬁne the adverse
effects.
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